Englander Institute for Precision Medicine
logo

Weill Cornell Medicine's Englander Institute for Precision Medicine is a large multi-disciplinary  institute that uses precision medicine technologies and informatics to uncover the molecular  mechanisms of disease and individualize disease treatment and prevention. 

Read more about us 

A Second Chance with Precision Medicine | Weill Cornell Medicine

A Second Chance, Thanks to Precision Medicine
After an eight-year journey, Cheryl Bonder is in remission due to the tenacity of Weill Cornell Medicine physicians and scientists. At WCM, we are committed to #ChangingMedicine and the standard of care with treatments as unique as our patients.

The EIPM offers genomic testing to impact clinical care and advance disease research. Patients and clinicians can learn about enrollment in clinical trials and research studies here.

Learn how the EIPM is translating innovative precision medicine technologies from research laboratories to our patient’s bedside.

Education


Check us out on X, formerly known as Twitter, for the latest precision medicine news.

Mapping the Evolution of Urinary Tract Cancer Cells

March 18, 2024

Researchers at Weill Cornell Medicine have performed the most comprehensive analysis to date of cancer of the ureters or the urine-collection cavities in the kidney, known as upper tract urothelial carcinoma (UTUC).  The study, which compared the characteristics of primary and metastatic tumors, provides new insights into the biology of these aggressive cancers and potential ways to treat them.

EIPM Researchers Earn Cancer Grand Challenges Funding Award to Study Cancer Inequity

March 6, 2024

Weill Cornell Medicine is part of an international team that has been awarded funding of up to $25 million over five years by Cancer Grand Challenges to study the causes of cancer inequities.

Deciphering the Male Breast Cancer Genome

March 5, 2024

Male breast cancer has distinct alterations in the tumor genome that may suggest potential treatment targets, according to a study by Weill Cornell Medicine investigators. They have conducted the first whole genome sequencing analysis of male breast cancer, which looked at the complete DNA landscape of tumor samples from 10 patients.

Philanthropic gifts, in all shapes and sizes, are vital to our mission of bringing precision medicine to every patient and to our recruitment of the world’s best and brightest clinical minds.